Further evidence in this presentation that the Dermatology Go to Market model is working and likely to be a big contributor to revenue and profit. Epiduo (IQVIA $210 US) launched Feb 22- Market share 56%Aczone (IQVIA $95 US) launched Feb 22. - Market share 31%Absorica (IQVIA $140US) launched Sept 21 - Market share now 45% up from 39 in February updateAddionally, Upsher-Smith , Mayne's Absorica partner, reported in May a 350% gain in revenue in dermatology due to Absorica.Also 2 days ago Torrent, Mayne's Aczone partner made a small comment about an increase in US revenue aided by the launch of Dapsone (Aczone)
(20min delay)